8-K filing — Azitra, Inc. (AZTR)
Filed: 2026-08-21 AccNo: 0001493152-26-039565 Size: 241 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Anitra Q2 EPS $(0.17) Misses $(0.12) Estimate
Anitra (AMEX:AZTR) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.12) by 54.55 percent. This is a 85.95 percent increase over losses of $(1.21) per share from the same
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Azitra Regains NYSE American Compliance
Azitra, Inc. ("Azitra" or the "Company") (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and
Azitra Reports Results From Two Ex Vivo Human Skin Tissue Studies Evaluating Distribution And Anti-Wrinkle Activity Of Filaggrin Domain Supernatant
ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin ("rHDfilaggrin"). This S. epidermis derived supernatant is in development as a high value